^
Association details:
| Biomarker: | ALK rearrangement |
|---|---|
| Cancer: | Lung Non-Small Cell Squamous Cancer |
| Drug Class: | ALK inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
ALK-rearranged squamous cell carcinoma of the lung
Published date:
02/09/2021
Excerpt:
A total of 20 cases received an ALK inhibitor as first- or second-line treatment which included 11 with a partial response (PR), four with SD, and five with PD. The DCR and ORR was 75.0% (15/20) and 55.0% (11/20), respectively….Patients with ALK-rearranged SCC obtained clinical benefit from ALK-inhibitor therapy, especially those who were non-smokers and whose tumors had been identified by IHC+/FISH+.
DOI:
10.1111/1759-7714.13818
